Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김현수 | - |
dc.date.accessioned | 2017-01-05T02:01:48Z | - |
dc.date.available | 2017-01-05T02:01:48Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 0014-2999 | - |
dc.identifier.other | OAK-6306 | - |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/233455 | - |
dc.description.abstract | Diabetes mellitus has been known to mitigate ischemic or pharmacologic preconditioning in ischemia-reperfusion injuries. Remifentanil is a widely used opioid in cardiac anesthesia that possesses a cardioprotective effect against ischemia-reperfusion. We evaluated whether diabetes affected remifentanil preconditioning induced cardioprotection in ischemia-reperfusion rat hearts in view of anti-apoptotic pathways of survival and Ca2+ homeostasis. Streptozotocin-induced, diabetic rats and age-matched wild-type Sprague-Dawley rats were subjected to a left anterior descending coronary artery occlusion for 30 min followed by 1 h of reperfusion. Each diabetic and wild-type rat was randomly assigned to the sham, ischemia-reperfusion only, or remifentanil preconditioning group. Myocardial infarct size, activities of ERK1/2, Bcl2, Bax and cytochrome c, and gene expression influencing Ca2+ homeostasis were assessed. Remifentanil preconditioning significantly reduced myocardial infarct size compared to ischemia-reperfusion only in wild-type rats but not in diabetic rats. Remifentanil preconditioning increased expression of ERK1/2 and anti-apoptotic protein Bcl-2 and decreased expression of pro-apoptotic proteins, Bax and cytochrome c, compared to ischemia-reperfusion only in wild-type rats. In diabetic rat hearts, however, remifentanil preconditioning failed to recover the phosphorylation state of ERK1/2 and to repress apoptotic signaling. In addition, diabetes minimized remifentanil induced modulation of abnormal changes in sarcoplasmic reticulum genes and proteins in ischemia-reperfusion rat hearts. In conclusion, diabetes mitigated remifentanil induced cardioprotection against ischemia-reperfusion, which might be associated with reduced recovery of the activities of proteins involved in anti-apoptotic pathways including ERK1/2 and the abnormal expression of sarcoplasmic reticulum genes as a result of ischemia-reperfusion in rat hearts. © 2009 Elsevier B.V. All rights reserved. | - |
dc.language | English | - |
dc.title | Diabetes mellitus mitigates cardioprotective effects of remifentanil preconditioning in ischemia-reperfused rat heart in association with anti-apoptotic pathways of survival | - |
dc.type | Article | - |
dc.relation.issue | 41277 | - |
dc.relation.volume | 628 | - |
dc.relation.index | SCI | - |
dc.relation.index | SCIE | - |
dc.relation.index | SCOPUS | - |
dc.relation.startpage | 132 | - |
dc.relation.lastpage | 139 | - |
dc.relation.journaltitle | European Journal of Pharmacology | - |
dc.identifier.doi | 10.1016/j.ejphar.2009.11.032 | - |
dc.identifier.wosid | WOS:000274784500019 | - |
dc.identifier.scopusid | 2-s2.0-73649115943 | - |
dc.author.google | Kim H.S. | - |
dc.author.google | Cho J.E. | - |
dc.author.google | Hwang K.C. | - |
dc.author.google | Shim Y.H. | - |
dc.author.google | Lee J.H. | - |
dc.author.google | Kwak Y.L. | - |
dc.contributor.scopusid | 김현수(57191717719;57191718092) | - |
dc.date.modifydate | 20230620101535 | - |